Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by Daniel LawRafael Salomão Romano and Samantha Salim of Daniel Law outline how the instructions will improve transparency and accountability in the Brazilian pharmaceutical patent scene -
Sponsored by Gün and PartnersSelin Sinem Erciyas and Zeynep Çağla Üstün of Gün and Partners discuss the recent court decision which helps clarify Article 86 of the Turkish IP Code
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Rajiv Suri of RNA, Technology and IP Attorneys outline how the Advertising Standards Council of India have reacted to increased online gaming trends during the COVID-19 pandemic
-
Sponsored by MaiwaldMarco Stief of Maiwald takes a closer look at the key elements of the scientific research initiative that succeeded the Horizon 2020 framework programme
-
Sponsored by IncoproColette Durst explains how she restructured the 3M team during COVID and why a pandemic is the perfect time to show IP worth
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Daleep Kumar of RNA, Technology and IP Attorneys explain how the Advertising Standards Council of India is acting to prevent misleading claims about coronavirus cures and remedies
